Drug intelligence / Profile preview

RH5.1 + AS01

Development stage: Phase 2
Lead developer: University of Oxford
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RH5.1 is a soluble protein vaccine candidate targeting blood-stage *Plasmodium falciparum* malaria. It is formulated with the AS01 adjuvant to enhance immune response. The vaccine aims to provide protection against malaria by inducing antibodies against the RH5 protein, which is crucial for the parasite's invasion of red blood cells.

Targets

BSG (Basigin)PfRH5

Beyond the preview

Go deeper on RH5.1 + AS01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RH5.1 + AS01.

Explore the full profile